Johnson & Johnson and BeiGene, Ltd.: A Comprehensive Revenue Analysis

Pharma Giants: A Decade of Revenue Growth

__timestampBeiGene, Ltd.Johnson & Johnson
Wednesday, January 1, 20141303500074331000000
Thursday, January 1, 2015881600070074000000
Friday, January 1, 2016107000071890000000
Sunday, January 1, 201723838700076450000000
Monday, January 1, 201819822000081581000000
Tuesday, January 1, 201942821200082059000000
Wednesday, January 1, 202030887400082584000000
Friday, January 1, 2021117628300078740000000
Saturday, January 1, 2022141592100079990000000
Sunday, January 1, 2023245877900085159000000
Monday, January 1, 202461350000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Giants: Johnson & Johnson vs. BeiGene, Ltd.

In the ever-evolving landscape of the pharmaceutical industry, Johnson & Johnson and BeiGene, Ltd. stand as two contrasting titans. Over the past decade, Johnson & Johnson has consistently demonstrated its dominance, with revenues peaking at approximately $85 billion in 2023, marking a steady growth of around 15% since 2014. In contrast, BeiGene, Ltd., a rising star in the biotech sector, has shown an impressive revenue surge, skyrocketing from a modest $13 million in 2014 to nearly $2.5 billion in 2023, reflecting a staggering growth rate of over 18,000%.

This analysis highlights the dynamic nature of the pharmaceutical market, where established giants and innovative newcomers coexist. As BeiGene continues to expand its footprint, the competition intensifies, promising exciting developments in the years to come.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025